


글로벌 제약사 파이프라인 분석

- Pfizer -

2022. 07.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	30	31%
Infectious	21	22%
Immunology	20	21%
Metabolic	11	12%
Cardiovascular	4	4%
Hematology	4	4%
Genitourinary	2	2%
Musculoskeletal	2	2%
Renal	1	1%
Neuroscience	1	1%
합계	96개	100%

• 물질별 파이프라인



물질	개수	비중
Small molecules	50	52%
Vaccine	16	17%
Antibody	11	12%
Protein	8	8%
N/A(Not Applicable)	5	5%
Gene Therapy	3	3%
Peptide	2	2%
ADC	1	1%
합계	96개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	PF-07265803			Dilated cardiomyopathy due to lamin A/C gene mutation	Small molecules	p38 mitogen-activated protein kinase(p38 MAPK)	p38 MARK Antagonist	Mono	-
2	Cardiovascular	Phase 2	APD418			Acute heart failure with reduced ejection fraction	Small molecules	Adrenergic receptor beta 3 (ADRB3)	ADRB3 antagonist & cardiac myotrope	Mono	-
3	Cardiovascular	Phase 2	APD791		temanogrel	Raynaud's phenomenon secondary to systemic sclerosis	Small molecules	Serotonin 2A (5-HT2A) receptor	5-HT2A receptor inverse agonist	Mono	-
4	Cardiovascular	Phase 2	APD791		temanogrel	Microvascular Obstruction	Small molecules	Serotonin 2A (5-HT2A) receptor	5-HT2A receptor inverse agonist	Mono	-
5	Genitourinary	Registration		Myfembree	estradiol + norethindrone acetate	Endometriosis	Peptide	GnRH receptor	GnRH receptor antagonist	Mono	-
6	Genitourinary	Phase 3		Myfembree	estradiol + norethindrone acetate	Contraceptive efficacy	Peptide	GnRH receptor	GnRH receptor antagonist	Mono	-
7	Hematology	Phase 3	PF-06741086		marstacimab	Hemophilia	Antibody	anti-Tissue Factor	anti-Tissue Factor Pathway inhibitor	Mono	-
8	Hematology	Phase 3	PF-06838435		fidanacogene elaparvovec	Hemophilia	Gene Therapy	coagulation factor IX	coagulation factor IX activator	Mono	-
9	Hematology	Phase 3	PF-07055480		griectocogene fitelparvovec	Hemophilia	Gene Therapy	coagulation factor VIII	coagulation factor VIII activator	Mono	-
10	Hematology	Phase 1	PF-07209326			Sickle cell disease	Antibody	E selectin(SELE)	SELE antagonist	Mono	-
11	Immunology	Phase 3	APD334		etrasimod	Ulcerative Colitis	Small molecules	S1P	S1P Inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
12	Immunology	Phase 3	PF-06651600		ritlecitinib	Alopecia Areata	Small molecules	JAK3/TEC	JAK3/TEC Inhibitor	Mono	-
13	Immunology	Phase 3	APD334		etrasimod	Ulcerative Colitis	Small molecules	S1P	S1P Inhibitor	Mono	-
14	Immunology	Phase 3	PF-06651600		ritlecitinib	Alopecia Areata	Small molecules	JAK3/TEC	JAK3/TEC Inhibitor	Mono	-
15	Immunology	Phase 2	APD334		etrasimod	Crohn's disease	Small molecules	S1P	S1P inhibitor	Mono	-
16	Immunology	Phase 2	APD334		etrasimod	Alopecia Areata	Small molecules	S1P	S1P inhibitor	Mono	-
17	Immunology	Phase 2	APD334		etrasimod	Eosinophilic Esophagitis	Small molecules	S1P	S1P inhibitor	Mono	-
18	Immunology	Phase 2	PF-06480605			Ulcerative Colitis	Antibody	TNFSF15	TNFSF15 blocker	Mono	-
19	Immunology	Phase 2	PF-06651600		ritlecitinib	Vitiligo	Small molecules	JAK3/TEC	JAK3/TEC inhibitor	Mono	-
20	Immunology	Phase 2	PF-06651600		ritlecitinib	Crohn's Disease	Small molecules	JAK3/TEC	JAK3/TEC inhibitor	Mono	-
21	Immunology	Phase 2	PF-06687234	Dekavil		Rheumatoid Arthritis	Protein	IL-10	IL-10 inhibitor	Mono	Philogen
22	Immunology	Phase 2	PF-06823859			Dermatomyositis	Antibody	interferon beta (IFNB1)	IFNB1 blocker	Mono	-
23	Immunology	Phase 2	PF-06835375			Immune Thrombocytopenic Purpura	N/A	CXCR5	anti-CXCR5	Mono	-
24	Immunology	Phase 2	PF-07038124			Atopic Dermatitis and Psoriasis	Small molecules	PDE4	Topical PDE4 inhibitor	Mono	-
25	Immunology	Phase 2	RIST4721			Palmoplantar Pustulosis	Small molecules	CXCR2	CXCR2 antagonist	Mono	-
26	Immunology	Phase 1	PF-06835375			Lupus	N/A	CXCR5	anti-CXCR5	Mono	-
27	Immunology	Phase 1	PF-07054894			Inflammatory Bowel Disease	Small molecules	CCR6	CCR6 Antagonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
28	Immunology	Phase 1	PF-07242813			Atopic Dermatitis	N/A	CD1A	CD1A inhibitor	Mono	-
29	Immunology	Phase 1	PF-07259955			Atopic Dermatitis	Small molecules	JAK	Topical Soft JAK Inhibitor	Mono	-
30	Immunology	Phase 1	PF-07295324			Atopic Dermatitis	Small molecules	JAK	Topical Soft JAK Inhibitor	Mono	-
31	Infectious	Registration		Paxlovid	Nirmatrelvir +ritonavir	COVID-19 Infection, high risk population	Small molecules	SARS-CoV-2 3CL pro tease	SARS-CoV-2 3CL protease inhibitor	Mono	-
32	Infectious	Registration	Covid-19 Vx	Comirnaty		COVID-19 Infection, pediatrics, 5-11yrs old	Vaccine	SARS-CoV-2 S	Prophylactic mRNA vaccine	Mono	BioNTech
33	Infectious	Registration	Covid-19 Vx	Comirnaty		COVID-19 Infection Booster	Vaccine	SARS-CoV-2 S	Prophylactic mRNA vaccine	Mono	BioNTech
34	Infectious	Registration	Covid-19 Vx	Comirnaty		COVID-19 Infection, pediatrics, 12-15yrs old	Vaccine	SARS-CoV-2 S	Prophylactic mRNA vaccine	Mono	BioNTech
35	Infectious	Phase 3	Covid-19 Vx	Comirnaty		COVID-19 Infection, pediatrics, 6-24 months	Vaccine	SARS-CoV-2 S	Prophylactic mRNA vaccine	Mono	BioNTech
36	Infectious	Phase 3	Covid-19 Vx	Comirnaty		COVID-19 Infection, pediatrics, 2-4yrs old	Vaccine	SARS-CoV-2 S	Prophylactic mRNA vaccine	Mono	BioNTech
37	Infectious	Phase 3	Omicron variant (Covid-19 Vx)			COVID-19 Infection	Vaccine	N/A	Prophylactic mRNA vaccine	Mono	BioNTech
38	Infectious	Phase 3	PF-06425090			Primary clostridioides difficile infection	Vaccine	N/A	Prophylactic vaccine	Mono	-
39	Infectious	Phase 3	PF-06482077			Invasive and non-invasive pneumococcal infections, pediatrics	Vaccine	N/A	Prophylactic vaccine	Mono	-
40	Infectious	Phase 3	PF-06886992			Serogroups ABCWY Meningococcal Infections, adolescent and young adults	Vaccine	Lipoprotein GNA1870	Prophylactic vaccine	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
41	Infectious	Phase 3	PF-06928316			Respiratory syncytial virus infection, older adult	Vaccine	N/A	Prophylactic vaccine	Mono	-
42	Infectious	Phase 3	PF-06928316			Respiratory syncytial virus infection, maternal	Vaccine	N/A	Prophylactic vaccine	Mono	-
43	Infectious	Phase 3	PF-06947387		aztreonam-avibactam	Infections from Gram-negative bacteria	Small molecules	Beta Lactamase(LACTB)	LACTB inhibitor	Mono	-
44	Infectious	Phase 3		Paxlovid	Nirmatrelvir +ritonavir	COVID-19 Infection, pediatrics	Small molecules	SARS-CoV-2 3CL protease	SARS-CoV-2 3CL protease inhibitor	Mono	-
45	Infectious	Phase 3		Paxlovid	Nirmatrelvir +ritonavir	COVID-19 Infection, post exposure prophylaxis	Small molecules	SARS-CoV-2 3CL protease	SARS-CoV-2 3CL protease inhibitor	Mono	-
46	Infectious	Phase 3		Paxlovid	Nirmatrelvir +ritonavir	COVID-19 Infection, standard risk population	Small molecules	SARS-CoV-2 3CL protease	SARS-CoV-2 3CL protease inhibitor	Mono	-
47	Infectious	Phase 2	APX001		fosmanogepix	Invasive fungal infections	Small molecules	Gwt1	Gwt1 inhibitor	Mono	Eisai
48	Infectious	Phase 2	PF-06760805			Invasive group B streptococcus infection, maternal	Vaccine	N/A	Prophylactic vaccine	Mono	-
49	Infectious	Phase 2	PF-06842433			Invasive and non-invasive pneumococcal infections, infants and children	Vaccine	N/A	Prophylactic vaccine	Mono	-
50	Infectious	Phase 2	PF-07307405			Lyme disease	Vaccine	N/A	Prophylactic vaccine	Mono	-
51	Infectious	Phase 1	PF-07252220			Influenza	Vaccine	N/A	Prophylactic mRNA vaccine	Mono	BioNTech
52	Metabolic	Registration	PF-06836922	Ngenla	somatrogon	Growth hormone deficiency, pediatrics	Protein	Growth Hormone Receptor (GHR)	GHR agonist	Mono	Opko

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
53	Metabolic	Phase 3	PF-06836922	Ngenla	somatrogon	Growth hormone deficiency, adult	Protein	Growth Hormone Receptor (GHR)	GHR agonist	Mono	-
54	Metabolic	Phase 2	PF-06865571		ervogastat	Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis	Small molecules	Diacylglycerol O-Acyltransferase 2 (DGAT2)	DGAT2 inhibitor	Mono	-
55	Metabolic	Phase 2	PF-06865571 + PF-05221304		ervogastat + clesacostat	Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis	Small molecules	Diacylglycerol O-Acyltransferase 2 (DGAT2); Acetyl CoA-Carboxylase (ACC)	DGAT2 inhibitor; ACC inhibitor	Combination	-
56	Metabolic	Phase 2	PF-06882961		danuglipron	Obesity	Small molecules	Glucagon-like peptide 1 receptor (GLP-1R)	GLP-1R agonist	Mono	-
57	Metabolic	Phase 2	PF-06882961		danuglipron	Diabetes Mellitus-Type 2	Small molecules	Glucagon-like peptide 1 receptor (GLP-1R)	GLP-1R agonist	Mono	-
58	Metabolic	Phase 1	PF-06882961 + PF-06865571			Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis	Small molecules	Glucagon-like peptide 1 receptor (GLP-1R), Diacylglycerol O-Acyltransferase 2 (DGAT2)	GLP-1R Agonist; DGAT2 Inhibitor	Combination	-
59	Metabolic	Phase 1	PF-06946860		ponsegromab	Cancer Cachexia and Heart Failure	Antibody	Growth Differentiation Factor 15 (GDF15)	GDF15 Monoclonal Antibody	Mono	-
60	Metabolic	Phase 1	PF-07081532			Diabetes Mellitus-Type 2 and Obesity	Small molecules	Glucagon-like peptide 1 receptor (GLP-1R)	GLP-1R Agonist	Mono	-
61	Metabolic	Phase 1	PF-07202954			Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis	N/A	Diacylglycerol O-Acyltransferase 2 (DGAT2)	DGAT2 Inhibitor	Mono	-
62	Metabolic	Phase 1	PF-07258669			Geriatric anorexia	Small molecules	Melanocortin-4 receptor (MC4R)	MC4R Antagonist	Mono	-
63	Musculoskeletal	Phase 3	PF-06939926		fordadistrogene movaparvovec	Duchenne muscular dystrophy ambulatory	Gene Therapy	Dystrophin(DMD)	DMD activator	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
64	Musculoskeletal	Phase 2	TA-46		recifercept	Achondroplasia	Protein	FGF	FGF inhibitor	Mono	-
65	Neuroscience	Phase 1	PF-06755347			Chronic inflammatory demyelinating polyneuropathy	Protein	N/A	Immunomodulation	Mono	-
66	Oncology	Phase 3	LGX818	Braftovi+Mektovi+Keytruda	encorafenib+binimetinib+pembrolizumab	BRAF-mutant metastatic/unresectable locally advanced melanoma	Small molecules	BRAF;MEK;PD-1	BRAF kinase inhibitor; MEK inhibitor; anti PD-1	Combination	-
67	Oncology	Phase 3	LGX818	Braftovi+Erbbitux	encorafenib+cetuximab	1L BRAF-mutant metastatic colorectal cancer	Small molecules	BRAF;EGFR	BRAF kinase inhibitor; anti EGFR	Combination	-
68	Oncology	Phase 3	mdv3100	Xtandi	enzalutamide	Non-metastatic high-risk castration sensitive prostate cancer	Small molecules	Androgen receptor	Androgen receptor inhibitor	Mono	-
69	Oncology	Phase 3	mdv3800	Talzenna	talazoparib	DDR-deficient metastatic castration sensitive prostate cancer	Small molecules	PARP	PARP inhibitor	Mono	-
70	Oncology	Phase 3	mdv3800	Talzenna	talazoparib	1L metastatic castration resistant prostate cancer	Small molecules	PARP	PARP inhibitor	Mono	-
71	Oncology	Phase 3	PD-0332991	Ibrance	palbociclib	ER+/HER2+ metastatic breast cancer	Small molecules	CDK4,6 kinase	CDK 4,6 kinase inhibitor	Mono	-
72	Oncology	Phase 3	PF-06801591+BCG		sasanlimab+Bacillus Calmette-Guerin	Non-muscle-invasive bladder cancer	Antibody	PD-1	Anti-PD-1	Combination	GC Pharma
73	Oncology	Phase 3	PF-06863135		Elranatamab	Multiple Myeloma double-class exposed	Antibody	BCMA/CD3	Bispecific antibody(BCMA, CD3)	Mono	-
74	Oncology	Phase 2	ARV-471			ER+/HER2- metastatic breast cancer	Small molecules	Estrogen receptor	Selective estrogen receptor degrader(SERD)	Mono	Arvinas

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
75	Oncology	Phase 2	Ibrance +ARV-471	Ibrance +ARV-471	Palbociclib +ARV-471	ER+/HER2- metastatic breast cancer	Small molecules	CDK4,6 kinase;estrogen receptor	CDK 4,6 kinase inhibitor ; Selective estrogen receptor degrader(SERD)	Combination	-
76	Oncology	Phase 2	PF-06863135		elranatamab	Multiple myeloma triple-class refractory	Antibody	BCMA/CD3	Bispecific antibody (BCMA, CD3)	Mono	-
77	Oncology	Phase 2	PF-07901801			Hematological malignancies	Protein	CD47	CD47 inhibitor	Mono	-
78	Oncology	Phase 2		Braftovi +Mektovi	Encorafenib +binimetinib	1L/2L BRAF-mutant metastatic NSCLC	Small molecules	BRAF	BRAF kinase inhibitor; MEK inhibitor	Combination	-
79	Oncology	Phase 1	PF-06647020			Cancer	ADC	protein tyrosine kinase 7 (PTK7)	Cytotoxic to cells expressing PTK7	Mono	Abbvie
80	Oncology	Phase 1	PF-06821497			Prostate Cancer	Small molecules	EZH2	EZH2 Inhibitor	Mono	-
81	Oncology	Phase 1	PF-06873600			Metastatic breast cancer	Small molecules	CDK 2, CDK4, CDK6	CDK 2, CDK4, CDK6 Inhibitor	Mono	-
82	Oncology	Phase 1	PF-06940434			Solid Tumors	N/A	Integrin alpha-V/beta-8	Integrin alpha-V/beta-8 Antagonist	Mono	-
83	Oncology	Phase 1	PF-07062119			Solid Tumors	Antibody	GUCY2C/CD3	Bispecific antibody (GUCY2C, CD3)	Mono	-
84	Oncology	Phase 1	PF-07104091			Metastatic breast cancer	Small molecules	CDK2	CDK2 Inhibitor	Mono	-
85	Oncology	Phase 1	PF-07209960			Solid Tumors	Protein	interleukin 15 (IL15)	IL15 Activator	Mono	-
86	Oncology	Phase 1	PF-07220060			Metastatic breast cancer	Small molecules	CDK4	CDK4 Inhibitor	Mono	-
87	Oncology	Phase 1	PF-07220060 +PF-0710409 +ET			Metastatic breast cancer	Small molecules	CDK4	CDK4 triplet	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
88	Oncology	Phase 1	PF-07248144			Metastatic breast cancer	Small molecules	KAT6A	KAT6A Epigenetic Modifier	Mono	-
89	Oncology	Phase 1	PF-07257876			NSCLC	Antibody	CD47/PD-L1	Bispecific antibody (CD47,PD-L1)	Mono	-
90	Oncology	Phase 1	PF-07260437			Metastatic breast cancer	Antibody	B7H4/CD3	Bispecific antibody (B7H4, CD3)	Mono	-
91	Oncology	Phase 1	PF-07263689			Solid Tumors	Vaccine	N/A	OBIR-2 Therapeutic Vaccine	Mono	-
92	Oncology	Phase 1	PF-07265028			Head and Neck Cancer	Small molecules	HPK1	HPK1 Inhibitor	Mono	-
93	Oncology	Phase 1	PF-07265807			Solid Tumors	Small molecules	AXL/MERTK	AXL/MERTK Inhibitor	Mono	-
94	Oncology	Phase 1	PF-07284890			Melanoma	Small molecules	BRAF	BRAF BP kinase Inhibitor	Mono	-
95	Oncology	Phase 1	PF-07284892			Cancer	Small molecules	SHP2	SHP2 tyrosine phosphatase Inhibitor	Mono	-
96	Renal	Phase 2	PF-06730512			Focal segmental glomerulosclerosis	Protein	FGF	FGF inhibitor	Mono	-

자료: Pfizer 홈페이지, BioCentury, GlobalData